Karyopharm Therapeutics (KPTI) Market Capitalization (2013 - 2026)

Karyopharm Therapeutics (KPTI) has reported Market Capitalization for 14 consecutive years, with $282.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 658.61% year-over-year to $282.7 million; the trailing twelve-month figure through Jun 2026 stood at $282.7 million (up 658.61% YoY), and the FY2025 full-year result was $80.5 million, down 5.67% from the prior year.
• Market Capitalization grew to $282.7 million in Q2 2026 per KPTI's latest filing, from $80.5 million in the prior quarter.
• Across five years, Market Capitalization topped out at $585.3 million in Q1 2022 and bottomed at $32.0 million in Q1 2025.
• Historically, Market Capitalization has averaged $207.6 million across 5 years, with a median of $153.5 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Market Capitalization slumped 81.78% in 2025, then jumped 658.61% in 2026.
• Over 5 years, Market Capitalization stood at $278.4 million in 2022, then tumbled by 64.28% to $99.4 million in 2023, then decreased by 14.21% to $85.3 million in 2024, then slipped by 5.67% to $80.5 million in 2025, then jumped by 251.29% to $282.7 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $282.7 million, $80.5 million, and $56.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.